Hematologic Oncology | Specialty

Dr. Giralt on Omidubicel Vs Standard Umbilical Cord Blood Transplant in Hematologic Malignancies

March 15th 2021

Sergio A. Giralt, MD, discusses the results of a phase 3 trial comparing omidubicel with standard umbilical cord blood transplant in hematologic malignancies.

Omidubicel Showcases Promising Outcomes in High-Risk Hematologic Cancers Following Myeloablation

March 15th 2021

Omidubicel was associated with a significantly improved median time to neutrophil engraftment compared with standard umbilical cord blood transplantation in patients with high-risk hematologic malignancies.

R2 Regimen for R/R Follicular Lymphoma

March 15th 2021

An overview of the MAGNIFY data and implications for treating appropriate patients with relapsed/refractory follicular lymphoma with the R2 regimen.

Investigators Focus Devimistat Study on Older Patients With AML

March 15th 2021

Devimistat, a small molecule that targets enzymes involved in cancer cell metabolism, holds promise for older patients with relapsed or refractory acute myeloid leukemia who typically have a poor prognosis with standard-of-care chemotherapy

Future Treatment Landscape of AML

March 15th 2021

Corey S. Cutler, MD, MPH, FRCPC; Adam Bagg, MD; Alexander E. Perl, MD, MS; Eunice S. Wang, MD; and Harry P. Erba, MD, PhD, share closing thoughts and emerging therapies on the horizon for the treatment of AML.

Maintenance Therapy Post-Transplant in AML

March 15th 2021

Patient selection for maintenance therapy post-allogeneic transplant in myeloid malignancies and thoughts on treatment of FLT3-mutated disease post-transplant with agents such as midostaurin.

PI3K Inhibitors for R/R Follicular Lymphoma

March 15th 2021

Recommendations for treating patients with relapsed/refractory follicular lymphoma with an available PI3K inhibitor and managing adverse events from treatment.

R/R DLBCL: Transplants in the Era of CAR-T

March 12th 2021

CAR T for R/R DLBCL: Improving Access and Utilization

March 12th 2021

FDA Extends Review Period for Belumosudil in Chronic GVHD

March 11th 2021

The FDA has extended the review period for the new drug application for belumosudil for use in patients with chronic graft-versus-host disease to allow for more time to review additional data submitted by the biopharmaceutical company.

ASH Takeaways and Future Directions for Multiple Myeloma

March 11th 2021

Paul G. Richardson, MD; Nina Shah, MD; David Siegel, MD, PhD; and Saad Z. Usmani, MD, provide closing thoughts and key takeaways on multiple myeloma from the 2020 ASH Virtual Meeting and future directions for disease management. 

Sequencing BCMA-Targeted Agents in RRMM

March 11th 2021

Insights on approaching the sequencing of BCMA-targeted agents and whether antigen loss is considered an issue in RRMM. 

Non-BCMA Specific Targets in RRMM

March 11th 2021

Examining non-BCMA BiTE (bispecific T-cell engager) approaches to therapy, such as talquetamab and BFCR4350A, for the treatment of RRMM. 

Dr. Goy on the Efficacy of Brexucabtagene Autoleucel in Relapsed/Refractory MCL

March 10th 2021

Andre Goy, MD, discusses the efficacy of brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma, as demonstrated in the phase 2 ZUMA-2 trial.

Dr. Neelapu on Managing Toxicities Associated with CAR T-Cell Products in Lymphoma

March 10th 2021

Sattva Neelapu, MD, discusses the management of toxicities associated with CAR T-cell products in patients with lymphoma.

Venetoclax/HMA Approach Revolutionizes Care for Certain Subsets of AML

March 10th 2021

Kira Gritsman, MD, PhD, discusses the significance of the VIALE-A trial examining venetoclax plus azacitidine in older patients with AML and the emergence of minimal residual disease as an important end point in clinical trials.

Polycythemia Vera: An Update on Clinical Trials

March 10th 2021

Experts discuss clinical trial updates in polycythemia vera, including data from RESPONSE, RESPONSE-2, an international observational study of ruxolitinib, and REVEAL.

PV Progression and Guideline-Directed Management

March 10th 2021

Ruben A. Mesa, MD, highlights signs of disease progression and the utilization of guideline recommendations in the occurrence of a thrombotic event when treating polycythemia vera.

D’Angelo Details Combos Designed to Produce Durable Activity in Relapsed/Refractory DLBCL

March 9th 2021

Christopher D'Angelo, MD, discusses emerging CAR T-cell therapies and the challenges with using a 5-drug regimen.

Belumosudil: Poised to Become Necessity in Chronic GVHD

March 9th 2021

Corey S. Cutler, MD, MPH, FRCPC, discusses the potential clinical implications should belumosudil gain FDA approval in chronic GVHD.